{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:22:39Z","timestamp":1771017759436,"version":"3.50.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NDT"],"DOI":"10.2147\/ndt.s9622","type":"journal-article","created":{"date-parts":[[2010,9,10]],"date-time":"2010-09-10T00:11:32Z","timestamp":1284077492000},"page":"197","source":"Crossref","is-referenced-by-count":5,"title":["Role and rationale for the use of milnacipran in the management of fibromyalgia"],"prefix":"10.2147","author":[{"given":"Michael","family":"Gendreau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,4]]},"container-title":["Neuropsychiatric Disease and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=6321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T18:01:29Z","timestamp":1477850489000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/role-and-rationale-for-the-use-of-milnacipran-in-the-management-of-fib-peer-reviewed-article-NDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ndt.s9622","relation":{},"ISSN":["1176-6328"],"issn-type":[{"value":"1176-6328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}